These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. Tedizolid: a new oxazolidinone antimicrobial. Kisgen JJ; Mansour H; Unger NR; Childs LM Am J Health Syst Pharm; 2014 Apr; 71(8):621-33. PubMed ID: 24688035 [TBL] [Abstract][Full Text] [Related]
31. In vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections. Prokocimer P; Bien P; Deanda C; Pillar CM; Bartizal K Antimicrob Agents Chemother; 2012 Sep; 56(9):4608-13. PubMed ID: 22687509 [TBL] [Abstract][Full Text] [Related]
32. Use of Translational Pharmacokinetic/Pharmacodynamic Infection Models To Understand the Impact of Neutropenia on the Efficacy of Tedizolid Phosphate. Xiao J; Gill C; Liang L; Liu J; Wu J; Feng HP; Flanagan S; Tan C; Flattery A Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373794 [TBL] [Abstract][Full Text] [Related]
33. A Phase 3, Randomized, Double-Blind Study Comparing Tedizolid Phosphate and Linezolid for Treatment of Ventilated Gram-Positive Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia. Wunderink RG; Roquilly A; Croce M; Rodriguez Gonzalez D; Fujimi S; Butterton JR; Broyde N; Popejoy MW; Kim JY; De Anda C Clin Infect Dis; 2021 Aug; 73(3):e710-e718. PubMed ID: 33720350 [TBL] [Abstract][Full Text] [Related]
34. Clinical safety and tolerability of tedizolid phosphate in the treatment of acute bacterial skin and skin structure infections. Hardalo C; Lodise TP; Bidell M; Flanagan S; De Anda C; Anuskiewicz S; Prokocimer P Expert Opin Drug Saf; 2018 Apr; 17(4):359-367. PubMed ID: 29528251 [TBL] [Abstract][Full Text] [Related]
35. In vitro activity of tedizolid and comparator agents against Gram-positive pathogens responsible for bone and joint infections. Ract P; Piau-Couapel C; Compain F; Auzou M; Michon J; Cattoir V J Med Microbiol; 2017 Oct; 66(10):1374-1378. PubMed ID: 28920854 [TBL] [Abstract][Full Text] [Related]
36. [Pharmacological action and clinical effect of tedizolid phosphate (SIVEXTRO Mori M; Takase A Nihon Yakurigaku Zasshi; 2020; 155(5):332-339. PubMed ID: 32879176 [TBL] [Abstract][Full Text] [Related]
37. In Vitro Activities of Tedizolid and Linezolid against Gram-Positive Cocci Associated with Acute Bacterial Skin and Skin Structure Infections and Pneumonia. Chen KH; Huang YT; Liao CH; Sheng WH; Hsueh PR Antimicrob Agents Chemother; 2015 Oct; 59(10):6262-5. PubMed ID: 26248355 [TBL] [Abstract][Full Text] [Related]
38. Tedizolid population pharmacokinetics, exposure response, and target attainment. Flanagan S; Passarell J; Lu Q; Fiedler-Kelly J; Ludwig E; Prokocimer P Antimicrob Agents Chemother; 2014 Nov; 58(11):6462-70. PubMed ID: 25136028 [TBL] [Abstract][Full Text] [Related]
39. Tedizolid (TR-701): a new oxazolidinone with enhanced potency. Kanafani ZA; Corey GR Expert Opin Investig Drugs; 2012 Apr; 21(4):515-22. PubMed ID: 22324973 [TBL] [Abstract][Full Text] [Related]
40. Characterization of the haematological profile of 21 days of tedizolid in healthy subjects. Lodise TP; Bidell MR; Flanagan SD; Zasowski EJ; Minassian SL; Prokocimer P J Antimicrob Chemother; 2016 Sep; 71(9):2553-8. PubMed ID: 27317442 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]